Financial Enhancement Group’s DexCom DXCM Stock Holding History

Financial Enhancement Group’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-14,308	Closed	-$963K	–	262
2020 Q1	$963K	Buy	+14,308	New	+$890K	0.29%	47

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Financial Enhancement Group's DXCM Position: Q2 2020 in Review

Financial Enhancement Group sold out of DexCom (DXCM) in Q2 2020, closing a stake of 14,308 shares — an estimated $963K sold.

Financial Enhancement Group first reported a position in DXCM in Q1 2020 and held it in 1 quarter. The position peaked at $963K in Q1 2020. 722 funds tracked by Wall St. Rank hold DXCM as of Q2 2020.

Financial Enhancement Group reported no remaining DexCom position as of Q2 2020 after selling out during the quarter.
Financial Enhancement Group sold 14,308 DexCom shares in Q2 2020, an estimated $963K.
Financial Enhancement Group first reported a position in DexCom in Q1 2020 and held it in 1 quarter.
Financial Enhancement Group's DexCom position peaked at $963K in Q1 2020.
722 funds tracked by Wall St. Rank held DexCom as of Q2 2020.

Based on Financial Enhancement Group's 13F filing for Q2 2020, filed 14 Aug 2020.